Vol. 17/No. 1 | Oncology Live®

January 15, 2016

Denise Yardley, MD, and Linda Vahdat, MD, explain the phase III METRIC trial and the potential importance of glembatumumab in triple-negative breast cancer.

December 29, 2015

Thomas F. Gajewski, MD, PhD, discusses how the field of immune checkpoints is expanding beyond PD-1 and CTLA-4.

December 29, 2015

Keith T. Flaherty, MD, discusses molecular testing issues and the use of combined BRAF/ MEK inhibition in patients with advanced/metastatic melanoma.

December 28, 2015

It is becoming increasingly clear that PD-1/ PD-L1 and CTLA-4 represent just the tip of the iceberg when it comes to manipulating the immune system to fight cancer, and the number of known checkpoints—and with it the list of potential drug targets—has expanded in recent years.

December 28, 2015

As clinical experience grows with new agents, combinations, and sequences of therapy, the use of molecular profiling in metastatic melanoma is likely to become an essential means of choosing among treatment options.

December 27, 2015

Philip W. Kantoff, MD, who has made many contributions in prostate cancer research at the laboratory and leadership levels, was honored in the Genitourinary Cancer category with a 2014 Giants of Cancer Care® award, a program that the Intellisphere® Oncology Specialty Group launched to honor leaders in the field.

December 26, 2015

One of the central reasons that curing cancer has been so problematic is the dysfunction of TP53, the single most common genetic alteration in cancer.

December 25, 2015

While major accomplishments in blood and marrow transplantation (BMT) were being made around the country, the first BMT program at Wake Forest Baptist came into view, a vision brought to life by David D. Hurd, MD.

December 24, 2015

Howard A. “Skip” Burris III, MD, offers his views on key developments in the oncology field.

December 23, 2015

In the three years since the FDA launched its breakthrough therapy program, the designation has become a coveted status for emerging agents as biopharmaceutical companies scramble to make their mark in an increasing competitive environment.

December 21, 2015

We’re always talking about the rapid pace of oncology drug development in this era, but perhaps nothing illustrates that trend so clearly as the events of one 15-day period in November.

December 21, 2015

It is simply unrealistic and highly counterproductive to the future of cancer care to believe that the only acceptable approach to determining the absolute or relative clinical utility of a specific drug, regimen, device, or procedure, is through the conduct of a so-called evidence-based randomized trial.

December 16, 2015

Although ovarian cancer remains a formidable challenge in the United States, therapeutic advances achieved during the past several years have provided specialists in gynecologic malignancies with more options than ever for treating patients.